CALC

SEC source: 0001209191-23-020684 · doc4.xml · nonDerivative · entry 1

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI, L.P.

Disclosed balance after: 703,388

F1 · price: Received in exchange for 24,423,158 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.

F2 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI, LP ("SVP VI, LP", together with Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the "Sanderling VI Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020682 · doc4.xml · derivative · entry 8

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,592

Underlying: Common Stock · 8,592 shares

Expires 2026-06-25

F11 · price: Received in exchange for a warrant to purchase 298,321 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F10 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020682 · doc4.xml · derivative · entry 7

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,592

Underlying: Common Stock · 8,592 shares

Expires 2026-02-22

F11 · price: Received in exchange for a warrant to purchase 298,321 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F10 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020682 · doc4.xml · derivative · entry 6

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,488

Underlying: Common Stock · 1,488 shares

Expires 2033-03-19

F3 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F9 · price: Received in exchange for a stock option to acquire 51,692 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F5 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of twelve (12) successive equal monthly installments.

SEC source: 0001209191-23-020682 · doc4.xml · derivative · entry 5

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,577

Underlying: Common Stock · 7,577 shares

Expires 2033-03-19

F3 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F8 · price: Received in exchange for a stock option to acquire 263,107 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F5 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of twelve (12) successive equal monthly installments.

SEC source: 0001209191-23-020682 · doc4.xml · derivative · entry 4

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,760

Underlying: Common Stock · 5,760 shares

Expires 2031-06-30

F3 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F7 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F6 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020682 · doc4.xml · derivative · entry 3

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,760

Underlying: Common Stock · 5,760 shares

Expires 2031-04-27

F3 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F7 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F5 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of twelve (12) successive equal monthly installments.

F6 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020682 · doc4.xml · derivative · entry 2

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,557

Underlying: Common Stock · 23,557 shares

Expires 2030-06-29

F3 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F4 · price: Received in exchange for a stock option to acquire 817,964 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F2 · derivative.exercise_date: Beginning on June 15, 2020, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020682 · doc4.xml · nonDerivative · entry 1

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 181,655

F1 · price: Received in exchange for 6,307,451 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.

SEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 19

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Valence Investments SPV V, LLC

Disclosed balance after: 9,935

Underlying: Common Stock · 9,935 shares

Expires 2026-06-25

F26 · price: Received in exchange for a stock option to acquire 344,934 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F14 · derivative.exercise_date: Immediately exercisable.

F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 18

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Valence Investments SPV V, LLC

Disclosed balance after: 9,935

Underlying: Common Stock · 9,935 shares

Expires 2026-02-22

F26 · price: Received in exchange for a stock option to acquire 344,934 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F14 · derivative.exercise_date: Immediately exercisable.

F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 17

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,793

Underlying: Common Stock · 2,793 shares

Expires 2031-04-27

F25 · price: Received in exchange for a warrant to purchase 96,970 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F24 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the warrant shall be exercisable in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 16

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,804

Underlying: Common Stock · 1,804 shares

Expires 2023-03-19

F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F23 · price: Received in exchange for a stock option to acquire 62,659 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F20 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 15

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,060

Underlying: Common Stock · 20,060 shares

Expires 2033-03-19

F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F22 · price: Received in exchange for a stock option to acquire 696,547 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F20 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 14

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,284

Underlying: Common Stock · 5,284 shares

Expires 2033-03-19

F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F21 · price: Received in exchange for a stock option to acquire 183,501 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F20 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 13

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,263

Underlying: Common Stock · 1,263 shares

Expires 2032-08-30

F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F19 · price: Received in exchange for a stock option to acquire 43,873 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F14 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 12

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,677

Underlying: Common Stock · 1,677 shares

Expires 2032-08-30

F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F18 · price: Received in exchange for a stock option to acquire 58,235 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F14 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 11

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,935

Underlying: Common Stock · 2,935 shares

Expires 2032-08-30

F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F17 · price: Received in exchange for a stock option to acquire 101,911 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F14 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 10

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,778

Underlying: Common Stock · 11,778 shares

Expires 2031-06-30

F16 · price: Received in exchange for a stock option to acquire 408,982 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F12 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 9

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,982

Underlying: Common Stock · 6,982 shares

Expires 2031-06-30

F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F13 · price: Received in exchange for a stock option to acquire 242,431 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F12 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 8

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,739

Underlying: Common Stock · 11,739 shares

Expires 2031-04-27

F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F15 · price: Received in exchange for a stock option to acquire 408,982 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F14 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 7

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,982

Underlying: Common Stock · 6,982 shares

Expires 2031-04-27

F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F13 · price: Received in exchange for a stock option to acquire 242,431 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F12 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 6

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,041

Underlying: Common Stock · 36,041 shares

Expires 2030-06-29

F10 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F11 · price: Received in exchange for a stock option to acquire 1,251,440 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F9 · derivative.exercise_date: 25% of the shares subject to the option vested on May 20, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.

SEC source: 0001209191-23-020680 · doc4.xml · derivative · entry 5

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,851

Underlying: Common Stock · 22,851 shares

Expires 2030-01-23

F8 · price: Received in exchange for a stock option to acquire 793,470 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F6 · derivative.exercise_date: 25% of the shares subject to the option vested on April 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.

F7 · derivative.exercise_date: 25% of the shares subject to the option vested on May 20, 2021 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.

SEC source: 0001209191-23-020680 · doc4.xml · nonDerivative · entry 4

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By IRA Financial Trust Company CFBO Eric W. Roberts

Disclosed balance after: 10,661

F5 · price: Received in exchange for 370,140 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

SEC source: 0001209191-23-020680 · doc4.xml · nonDerivative · entry 3

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Valence Investments SPV VI, LLC

Disclosed balance after: 316,109

F4 · price: Received in exchange for 10,975,977 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020680 · doc4.xml · nonDerivative · entry 2

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Valence Investments SPV V, LLC

Disclosed balance after: 66,228

F3 · price: Received in exchange for 2,299,564 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020680 · doc4.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · Chief Business Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Valence Investments SPV IV, LLC

Disclosed balance after: 356,989

F1 · price: Received in exchange for an aggregate of 12,395,423 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.

F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020683 · doc4.xml · derivative · entry 2

Shaw Allan · CIK 0001626850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 744

Underlying: Common Stock · 744 shares

Expires 2032-11-21

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F5 · price: Received in exchange for a stock option to acquire 25,846 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F3 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of twelve (12) successive equal monthly installments.

SEC source: 0001209191-23-020683 · doc4.xml · derivative · entry 1

Shaw Allan · CIK 0001626850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,880

Underlying: Common Stock · 2,880 shares

Expires 2031-12-30

F2 · price: Received in exchange for a stock option to acquire 100,000 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.

F1 · derivative.exercise_date: Beginning on October 12, 2021, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments.

SEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 13

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,877

Underlying: Common Stock · 1,877 shares

Expires 2023-03-19

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F17 · price: Received in exchange for a stock option to acquire 65,191 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F14 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 12

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,991

Underlying: Common Stock · 18,991 shares

Expires 2033-03-19

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F16 · price: Received in exchange for a stock option to acquire 659,413 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F14 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 11

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,090

Underlying: Common Stock · 2,090 shares

Expires 2033-03-19

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F15 · price: Received in exchange for a stock option to acquire 72,589 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F14 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 10

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,954

Underlying: Common Stock · 1,954 shares

Expires 2032-08-30

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F13 · price: Received in exchange for a stock option to acquire 67,873 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F2 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 9

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 661

Underlying: Common Stock · 661 shares

Expires 2032-08-30

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F12 · price: Received in exchange for a stock option to acquire 22,977 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F2 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 8

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,472

Underlying: Common Stock · 5,472 shares

Expires 2032-07-12

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F11 · price: Received in exchange for a stock option to acquire 190,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F2 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 7

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,264

Underlying: Common Stock · 7,264 shares

Expires 2031-06-30

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F9 · price: Received in exchange for a stock option to acquire 252,226 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F8 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 6

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,147

Underlying: Common Stock · 13,147 shares

Expires 2031-04-27

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F10 · price: Received in exchange for a stock option to acquire 456,522 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F2 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 5

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,264

Underlying: Common Stock · 7,264 shares

Expires 2031-04-27

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F9 · price: Received in exchange for a stock option to acquire 252,226 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F8 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 4

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,647

Underlying: Common Stock · 21,647 shares

Expires 2030-06-29

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F7 · price: Received in exchange for a stock option to acquire 751,649 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F6 · derivative.exercise_date: 25% of the shares subject to the option vested on June 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.

SEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 3

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,640

Underlying: Common Stock · 8,640 shares

Expires 2029-04-24

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F5 · price: Received in exchange for a stock option to acquire 300,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F2 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 2

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,777

Underlying: Common Stock · 22,777 shares

Expires 2028-08-01

F3 · price: Received in exchange for a stock option to acquire 790,880 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F2 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020679 · doc4.xml · nonDerivative · entry 1

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,944

F1 · price: Received in exchange for 414,706 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.

SEC source: 0001209191-23-027196 · doc4.xml · derivative · entry 5

Valence Investments SPV IV LLC · CIK 0001812080 · 10% owner

Valence Investments SPV V, LLC · CIK 0001854361 · 10% owner

Valence Investments SPV VI, LLC · CIK 0001971787 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Valence Investments SPV V, LLC

Disclosed balance after: 9,935

Underlying: Common Stock · 9,935 shares

Expires 2026-06-25

F5 · price: Received in exchange for a warrant to acquire 344,934 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F4 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-027196 · doc4.xml · derivative · entry 4

Valence Investments SPV IV LLC · CIK 0001812080 · 10% owner

Valence Investments SPV V, LLC · CIK 0001854361 · 10% owner

Valence Investments SPV VI, LLC · CIK 0001971787 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Valence Investments SPV V, LLC

Disclosed balance after: 9,935

Underlying: Common Stock · 9,935 shares

Expires 2026-02-22

F5 · price: Received in exchange for a warrant to acquire 344,934 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F4 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-027196 · doc4.xml · nonDerivative · entry 3

Valence Investments SPV IV LLC · CIK 0001812080 · 10% owner

Valence Investments SPV V, LLC · CIK 0001854361 · 10% owner

Valence Investments SPV VI, LLC · CIK 0001971787 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Valence Investments SPV VI, LLC

Disclosed balance after: 316,109

F3 · price: Received in exchange for 10,975,977 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

SEC source: 0001209191-23-027196 · doc4.xml · nonDerivative · entry 2

Valence Investments SPV IV LLC · CIK 0001812080 · 10% owner

Valence Investments SPV V, LLC · CIK 0001854361 · 10% owner

Valence Investments SPV VI, LLC · CIK 0001971787 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Valence Investments SPV V, LLC

Disclosed balance after: 66,228

F2 · price: Received in exchange for 2,299,564 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

SEC source: 0001209191-23-027196 · doc4.xml · nonDerivative · entry 1

Valence Investments SPV IV LLC · CIK 0001812080 · 10% owner

Valence Investments SPV V, LLC · CIK 0001854361 · 10% owner

Valence Investments SPV VI, LLC · CIK 0001971787 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 356,989

F1 · price: Received in exchange for an aggregate of 12,395,423 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.

SEC source: 0001209191-23-027199 · doc4.xml · derivative · entry 2

Geffken Daniel E. · CIK 0001314756 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · By SG Dan Equity Holdings, LLC

Disclosed balance after: 5,760

Underlying: Common Stock · 5,760 shares

Expires 2030-10-30

F3 · price: Received in exchange for a warrant to purchase 200,000 shares of common stock of CalciMedica pursuant to the Merger Agreement. Upon the closing of the Merger, each outstanding warrant to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into a warrant to purchase the Issuer's common stock

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-027199 · doc4.xml · derivative · entry 1

Geffken Daniel E. · CIK 0001314756 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · By SG Dan Equity Holdings, LLC

Disclosed balance after: 11,520

Underlying: Common Stock · 11,520 shares

Expires 2030-11-09

F2 · price: Received in exchange for a warrant to acquire 400,000 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding warrant to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into a warrant to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.

F1 · derivative.exercise_date: Immediately exercisable.